TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03370952

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laproscopy
Description: laparoscopic ovarian cystectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined laproscopic and minilaparotomy ovarian cystectomy
Description: Under general anaesthesia, the patient is placed in the modified dorsal lithotomy position a 10-mm umbilical trocar is inserted. A panoramic view of the pelvis was obtained together with full assessment of the ovarian mass(es).~Aspiration of the cyst:Delivery of affected ovary outside the abdominal cavity:~Ovarian cystectomy:~Re-introduction of the ovary to inside the abdominal cavity:
Study: NCT03652818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Op pregabalin
Description: Pre-op pregabalin will be administered 60 min prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Op Placebo 1
Description: Placebo 1 will be administered 60 min prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Op Placebo 1
Description: Placebo 1 will be administered 60 min prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Op Placebo 1
Description: Placebo 1 will be administered 60 min prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Op Placebo 1
Description: Placebo 1 will be administered 60 min prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Op pregabalin
Description: Post-op pregabalin will be administered Post-operatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Op pregabalin
Description: Post-op pregabalin will be administered Post-operatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Op Placebo 1
Description: Placebo 1 will be administered post-operatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Op Placebo 1
Description: Placebo 1 will be administered post-operatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Op Placebo 1
Description: Placebo 1 will be administered post-operatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Op Placebo 2
Description: Placebo 2 will be administered post-operatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Op Placebo 2
Description: Placebo 2 will be administered post-operatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Op acetaminophen
Description: Acetaminophen will be administered Post-operatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Op acetaminophen
Description: Acetaminophen will be administered Post-operatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Op acetaminophen
Description: Acetaminophen will be administered Post-operatively.
Study: NCT00524433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tezosentan
Description: tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4 mL/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01614652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioKinetix Parachute Implant and All Appropriate Medical Therapy (AAMT)
Description: CardioKinetix Parachute implant and all appropriate medical therapy
Study: NCT01682096

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: computed coronary angiography
Description: Patients will be pre-medicated with atenolol 50 mg 1h prior to the scan.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exercise stress echocardiography
Description: Limited by symptoms
Study: NCT03186053

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: .Loading dose followed by continuous infusion in operation
Study: NCT02912923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual + Force Feedback
Description: Visual Feedback- Monitor displays two cursors that will represent the participant's hands, the cursors will fill with red ink as the user starts to compensate outside a normal error band. The amount of ink will increase proportionally to the magnitude of trunk compensation.~Force Feedback- Cues will be provided as resistance to move the robots' handles. These cues will be applied when the user moves outside a normal error band. The magnitude of the cue will be proportional to the magnitude of trunk compensation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual + Force Feedback
Description: Visual Feedback- Monitor displays two cursors that will represent the participant's hands, the cursors will fill with red ink as the user starts to compensate outside a normal error band. The amount of ink will increase proportionally to the magnitude of trunk compensation.~Force Feedback- Cues will be provided as resistance to move the robots' handles. These cues will be applied when the user moves outside a normal error band. The magnitude of the cue will be proportional to the magnitude of trunk compensation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual + Force + Game Scores Feedback
Description: Visual Feedback- Monitor displays two cursors that will represent the participant's hands, the cursors will fill with red ink as the user starts to compensate outside a normal error band. The amount of ink will increase proportionally to the magnitude of trunk compensation.~Force Feedback- Cues will be provided as resistance to move the robots' handles. These cues will be applied when the user moves outside a normal error band. The magnitude of the cue will be proportional to the magnitude of trunk compensation.~Game Scores- Numerical score displayed next to the cursors. The participant will be rewarded with more points when less compensation is exhibited, or with less points when an increased level of compensation is measured.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual + Force + Game Scores Feedback
Description: Visual Feedback- Monitor displays two cursors that will represent the participant's hands, the cursors will fill with red ink as the user starts to compensate outside a normal error band. The amount of ink will increase proportionally to the magnitude of trunk compensation.~Force Feedback- Cues will be provided as resistance to move the robots' handles. These cues will be applied when the user moves outside a normal error band. The magnitude of the cue will be proportional to the magnitude of trunk compensation.~Game Scores- Numerical score displayed next to the cursors. The participant will be rewarded with more points when less compensation is exhibited, or with less points when an increased level of compensation is measured.
Study: NCT04050176

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypnotic Medication Open-Label Taper
Description: Participants will have their soporific hypnotic medication dosage reduced by 25% every two weeks during a 10 week open-label tapering period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnotic Medication Blinded Taper
Description: Participants will have their soporific hypnotic medication dosage reduced by 25% every two weeks during a 10 week blinded tapering period.
Study: NCT02908932

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phospholipid-bound omega-3 supplement
Description: The dietary supplement is produced by Aker BioMarine. These krill oil capsules received a GRAS status approval from the U.S. Food and Drug Administration (FDA) in 2010. Aker BioMarine has a new pending application (2015) with the U.S. FDA for GRAS status for its new product on which this study capsule is based. Aker BioMarine markets a number of different krill-based omega-3 supplement products in the U.S. The US Food and Drug Administration (FDA) has determined that an Investigator New Drug (IND) Application is not required for this study. This phospholipid-bound omega-3 dietary supplement is provided in capsule form.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Placebo capsules that are identical in size and color to the experimental but contain an equal amount of macadamia nut oil.
Study: NCT03310034

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NAD-precursors
Description: Intervention product containing the NAD+-precursors nicotinic acid, nicotinamide, and tryptophan (total of 204 NE per serving) in a whey protein source for 31 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control product containing amino-acid mixture resembling whey-protein not containing the NAD+-precursors nicotinic acid, nicotinamide, and tryptophan. To be taken for 31 days.
Study: NCT02261987

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autogenic drainage (AD)
Description: It will be apply in one only session. The time spent during this bronchial drainage session will be 30 minutes All patients will perform all interventions in a randomized order.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistive inspiratory manoeuvre (RIM)
Description: It will be apply in one only session. The time spent during this bronchial drainage session will be 30 minutes All patients will perform all interventions in a randomized order.
Study: NCT01737606

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fast Cerebral Pulsatility Imaging
Description: Cerebral ultrasonic exploration using with neuro-navigation system : 4 acquisitions on 12 or 6 section planes
Study: NCT01930539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultraviolet B lamp
Description: Ultraviolet-Fluorescent lamp (KBD, Inc, Crescent Springs, Kentucky, USA) was designed to use Ultraviolet B emitting fluorescent bulbs that have lower heat emission and allows a larger area of skin exposure. The Lamp is equipped with a timer for improved safety. This device is FDA (Food and Drug Administration) approved.
Study: NCT04854239

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Half-guided implant placement
Description: The surgery was performed under local anaesthesia in both groups, half-guided implant placement was carried out based on randomization.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Half-guided implant placement
Description: The surgery was performed under local anaesthesia in both groups, half-guided implant placement was carried out based on randomization.
Study: NCT03318185

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gasless single-port laparoscopic surgery
Description: The single-port laparoscopic surgery is performed when the maneuvering room is provided by external suspension system.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: conventional laparoscopic surgery
Description: The multi-port laparoscopic surgery is performed when the belly is inflated with carbon dioxide to provide maneuvering room.
Study: NCT02261987

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistive inspiratory manoeuvre+autogenic drainage
Description: It will be apply in one only session. The time spent during this bronchial drainage session will be 30 minutes All patients will perform all interventions in a randomized order.
Study: NCT02833870

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Musical intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-musical (cooking) intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control with no intervention
Study: NCT03683303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile applications (APP)
Description: the experimental group receiving education using Mobile Application (APP), collected data using Wound Care Knowledge Scale, Wound Care Skills Scale, State Trait Anxiety Inventory and Heart Rate Variability at three phases, including before the intervention (T1), after 3 times of intervention (T2), and before discharge from hospital (T3). The SPSS 22.0 for Windows was used for statistics analyses.
Study: NCT00495053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hMaxi-K
Description: Two dose levels (5000 µg/90 mL intravesical instillation and 10000 µg/90 mL intravesical instillation)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hMaxi-K
Description: Two dose levels (5000 µg/90 mL intravesical instillation and 10000 µg/90 mL intravesical instillation)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo (PBS-20% sucrose)
Study: NCT04217759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle intervention
Description: The main goal was to provide knowledge and skills for targeted population in order for them to adapt healthy lifestyle throughout their life. At the end of intervention, participants were expected to be fully equipped with necessary knowledge and fundamental skills in adapting and maintaining healthy lifestyle throughout their life. Gradual improvements were emphasised and at least 5% loss of initial body weight was expected, aiming for at least 0.5% loss in the first month.~It was divided into three phases (preparation, implementation, maintenance) focusing on PA and diet, in which self-efficacy enhancement and self-regulatory skills were emphasised during the first month of intervention.
Study: NCT04367298

Intervention type: BEHAVIORAL
Intervention: Chronoprevention
Description: Preventive measures will be focused on organizational, educational and behavioural elements related to older people and healthcare professionals
Study: NCT01591148

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Morbidly obese subjects (body mass index greater than 40)and control subjects (body mass index 20-25) will be given propofol for induction of general anesthesia. Plasma samples will be taken to ascertain drug concentration over time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Morbidly obese subjects (body mass index greater than 40)and control subjects (body mass index 20-25) will be given propofol for induction of general anesthesia. Plasma samples will be taken to ascertain drug concentration over time.
Study: NCT04064268

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey
Description: 45 g whey + 20 g maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey
Description: 45 g whey + 20 g maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3-OHB + Whey
Description: 50 g ketone + 45 g whey + 20 g maltodextrin
Study: NCT03256617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive reassurance training
Description: The 2-day training program includes 3 sessions that will consist of interactive didactic lectures, solving case studies and role-playing activities. The first session uses lecture and cases to present models of pain and disability, evidence based predictors of disability and delayed recovery and evidence based interventions for patients with low back pain. The second session uses role playing and case studies help the providers to 1) develop skills in identifying maladaptive beliefs about pain in patients with low back pain and 2) develop the skills to address diagnostic uncertainty and negative pain beliefs and 3) develop skills to educate patients with low back pain. The third session will use role playing and case studies to refine the provider' skills in providing cognitive reassurance to patients with low back pain.
Study: NCT02238808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Eligible participants will take 2 mg Estradiol 3 times daily for 7-14 days pre-surgery.
Study: NCT03091153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Review
Description: In depth medication review with a focus on deprescribing
Study: NCT00239720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hOKT3gamma1(Ala-Ala)
Description: Escalating dose given IV over 5 days (1mg, 2mg, 4mg on days 3-5) of each 28 day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous dose of placebo given over 5 days of each 28 day cycle
Study: NCT02791269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: 180 mcg SC injection QW for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: 180 mcg SC injection QW for 48 weeks.
Study: NCT00807066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib 250 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum
Description: Platinum based chemotherapy with cycles every 21 days
Study: NCT03456661

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: Infiltration with 0.25% 29,5ml + 0,5ml physiologic serum (total volume 30ml), US guided, using pectoralis block technique.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine + Dexmedetomidine
Description: Infiltration with chirocaine 0.25% 29,5ml + 0,5ml dexmedetomidine (50µg) (total volume 30ml), US guided, using pectoralis block technique.
Study: NCT01078038

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cypher
Description: Sirolimus-eluting stent implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience V
Description: Everolimus-eluting Stent implantation
Study: NCT00368251

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Pharmaceutical Form: Tablet~* Concentration: 2.5 mg, 25 mg and 50 mg~* Route of Administration: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRV 2.5 mg
Description: * Pharmaceutical Form: Tablet~* Concentration: 2.5 mg~* Route of Administration: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRV 25 mg
Description: * Pharmaceutical Form: Tablet~* Concentration: 25 mg~* Route of Administration: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRV 50 mg
Description: * Pharmaceutical Form: Tablet~* Concentration: 50 mg~* Route of Administration: Oral use
Study: NCT00896493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: ATG will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: 5 mg/kg PO or IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Lymphoid radiation
Description: TLI is administered ten times in 80c- 120c Gy fractions on day -11 through day -7 and day -4 through day -1
Study: NCT03598426

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Conventional arm will only use oral dexamethasone as intervention; Short-Course arm will only use intravenous dexamethasone as intervention; Combined arm will use both oral and intravenous dexamethasone as intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Conventional arm will only use oral dexamethasone as intervention; Short-Course arm will only use intravenous dexamethasone as intervention; Combined arm will use both oral and intravenous dexamethasone as intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Conventional arm will only use oral dexamethasone as intervention; Short-Course arm will only use intravenous dexamethasone as intervention; Combined arm will use both oral and intravenous dexamethasone as intervention
Study: NCT03469544

Intervention type: OTHER
Intervention: complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body specific test Real time polymerase chain reaction
Description: complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body .~specific test is quantitation of long non coding RNA HOTAIR by Real time polymerase chain reaction in peripheral blood,Enzyme linked Immunosorbent Assay for serum midkine level

Intervention type: OTHER
Intervention: complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body specific test Real time polymerase chain reaction
Description: complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body .~specific test is quantitation of long non coding RNA HOTAIR by Real time polymerase chain reaction in peripheral blood,Enzyme linked Immunosorbent Assay for serum midkine level

Intervention type: OTHER
Intervention: complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body specific test Real time polymerase chain reaction
Description: complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body .~specific test is quantitation of long non coding RNA HOTAIR by Real time polymerase chain reaction in peripheral blood,Enzyme linked Immunosorbent Assay for serum midkine level
Study: NCT00963534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide, bendamustine, rituximab
Description: Phase I: Maximally tolerable dose of lenalidomide will be determined, starting with 5 mg per day, and up to maximally 25 mg per day. This treatment is given in combination with bendamustine and rituximab.~Phase II: Determination of progression free survival with treatment with lenalidomide (dosing determined in phase I) in combination with bendamustine and rituximab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide, bendamustine, rituximab
Description: lenalidomide: day 1-21, maximum 13 cycles bendamustine: days 1-2, cycle 1-6 rituximab: day1, cycle 1-6
Study: NCT03683303

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: oral education
Description: the control group receiving the oral education, collected data using Wound Care Knowledge Scale, Wound Care Skills Scale, State Trait Anxiety Inventory and Heart Rate Variability at three phases, including before the intervention (T1), after 3 times of intervention (T2), and before discharge from hospital (T3).
Study: NCT00379288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate combination MDI 200/10 mcg BID
Description: MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate combination MDI 400/10 mcg BID
Description: MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone/Salmeterol 250/50 mcg BID
Description: F/SC 250/50 twice daily for 1 year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone/Salmeterol 500/50 mcg BID
Description: F/SC 500/50 twice daily for 1 year